The post Alnylam Pharmaceuticals (ALNY) extending rally in final stage from April-2025 low appeared on BitcoinEthereumNews.com. Alnylam Pharmaceuticals Inc., (ALNY) discovers, develops & commercializes therapeutics based on ribonucleic acid interference. It comes under Healthcare – Biotech sector & trades as “ALNY” ticker at Nasdaq. As discussed in the last article, ALNY ended (4) pullback at $442.51 low & resume higher in (5). It favors rally in (5) towards $494.95 – $511.13 area as minimum extension to extend April cycle. It already reached the minimum level expected in last article, so chasing rally is risky now. But we like to buy the next correction in ((4)) at extreme area, when reach against April-2025 low. ALNY – Elliott Wave latest weekly view  It ended ((I)) at $140 high since inception in June-2025 & ((II)) pullback at $31.38 low in October-2016. Above there, it is showing nest as the part of (III) of ((III)). It placed (I) of ((III)) at $153.99 high in March-2018 & (II) at $60.27 low in December-2018. Within (III), it placed I at $242.97 high in December-2022 as diagonal & II at $141.97 low in April-2024. It ended ((1)) at $212 high, ((2)) at $117.58 low, ((3)) at $236.80 high, ((4)) at $181.65 low & ((5)) at $242.97 high. It corrected II in zigzag correction ended at 0.50 Fibonacci retracement of I. ALNY – Elliott Wave view from 9.08.2025  Above April-2024 low of II, it placed ((1)) of III at $304.39 high & ((2)) at $205.87 low on 4.07.2025 low. Currently, it favors rally in ((3)) of III & reached 1.618 Fib extension of ((1)). Yet, it expects small upside to finish it before correcting next in ((4)). Within ((3)), it placed (1) at $333.70 high, (2) at $309.57 low, (3) at $469.81 high, (4) at $442.51 low & favors rally in (5). It expects rally in (5) towards $494.95 – $511.13 area to finish ((3)) before correcting in… The post Alnylam Pharmaceuticals (ALNY) extending rally in final stage from April-2025 low appeared on BitcoinEthereumNews.com. Alnylam Pharmaceuticals Inc., (ALNY) discovers, develops & commercializes therapeutics based on ribonucleic acid interference. It comes under Healthcare – Biotech sector & trades as “ALNY” ticker at Nasdaq. As discussed in the last article, ALNY ended (4) pullback at $442.51 low & resume higher in (5). It favors rally in (5) towards $494.95 – $511.13 area as minimum extension to extend April cycle. It already reached the minimum level expected in last article, so chasing rally is risky now. But we like to buy the next correction in ((4)) at extreme area, when reach against April-2025 low. ALNY – Elliott Wave latest weekly view  It ended ((I)) at $140 high since inception in June-2025 & ((II)) pullback at $31.38 low in October-2016. Above there, it is showing nest as the part of (III) of ((III)). It placed (I) of ((III)) at $153.99 high in March-2018 & (II) at $60.27 low in December-2018. Within (III), it placed I at $242.97 high in December-2022 as diagonal & II at $141.97 low in April-2024. It ended ((1)) at $212 high, ((2)) at $117.58 low, ((3)) at $236.80 high, ((4)) at $181.65 low & ((5)) at $242.97 high. It corrected II in zigzag correction ended at 0.50 Fibonacci retracement of I. ALNY – Elliott Wave view from 9.08.2025  Above April-2024 low of II, it placed ((1)) of III at $304.39 high & ((2)) at $205.87 low on 4.07.2025 low. Currently, it favors rally in ((3)) of III & reached 1.618 Fib extension of ((1)). Yet, it expects small upside to finish it before correcting next in ((4)). Within ((3)), it placed (1) at $333.70 high, (2) at $309.57 low, (3) at $469.81 high, (4) at $442.51 low & favors rally in (5). It expects rally in (5) towards $494.95 – $511.13 area to finish ((3)) before correcting in…

Alnylam Pharmaceuticals (ALNY) extending rally in final stage from April-2025 low

Alnylam Pharmaceuticals Inc., (ALNY) discovers, develops & commercializes therapeutics based on ribonucleic acid interference. It comes under Healthcare – Biotech sector & trades as “ALNY” ticker at Nasdaq.

As discussed in the last article, ALNY ended (4) pullback at $442.51 low & resume higher in (5). It favors rally in (5) towards $494.95 – $511.13 area as minimum extension to extend April cycle. It already reached the minimum level expected in last article, so chasing rally is risky now. But we like to buy the next correction in ((4)) at extreme area, when reach against April-2025 low.

ALNY – Elliott Wave latest weekly view

 It ended ((I)) at $140 high since inception in June-2025 & ((II)) pullback at $31.38 low in October-2016. Above there, it is showing nest as the part of (III) of ((III)). It placed (I) of ((III)) at $153.99 high in March-2018 & (II) at $60.27 low in December-2018. Within (III), it placed I at $242.97 high in December-2022 as diagonal & II at $141.97 low in April-2024. It ended ((1)) at $212 high, ((2)) at $117.58 low, ((3)) at $236.80 high, ((4)) at $181.65 low & ((5)) at $242.97 high. It corrected II in zigzag correction ended at 0.50 Fibonacci retracement of I.

ALNY – Elliott Wave view from 9.08.2025 

Above April-2024 low of II, it placed ((1)) of III at $304.39 high & ((2)) at $205.87 low on 4.07.2025 low. Currently, it favors rally in ((3)) of III & reached 1.618 Fib extension of ((1)). Yet, it expects small upside to finish it before correcting next in ((4)). Within ((3)), it placed (1) at $333.70 high, (2) at $309.57 low, (3) at $469.81 high, (4) at $442.51 low & favors rally in (5). It expects rally in (5) towards $494.95 – $511.13 area to finish ((3)) before correcting in ((4)). If it breaks above $511.13, then it can extend up to $570.76 to finish ((3)). Chasing longs can be risky now. But we like to buy the next correction in ((4)) in 3, 7 or 11 swings against 4.07.2025 low. 

Source: https://www.fxstreet.com/news/alnylam-pharmaceuticals-alny-extending-rally-in-final-stage-from-april-2025-low-202510281236

Market Opportunity
WorldAssets Logo
WorldAssets Price(INC)
$0.6659
$0.6659$0.6659
-1.59%
USD
WorldAssets (INC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

YouTube Advertising Formats: A Complete Guide for Marketers

YouTube Advertising Formats: A Complete Guide for Marketers

In today’s fast-evolving digital landscape, YouTube has emerged as one of the most powerful platforms for marketers looking to engage audiences through video. With
Share
Techbullion2026/01/21 01:49
SEC clears framework for fast-tracked crypto ETF listings

SEC clears framework for fast-tracked crypto ETF listings

The post SEC clears framework for fast-tracked crypto ETF listings appeared on BitcoinEthereumNews.com. The Securities and Exchange Commission has approved new generic listing standards for spot crypto exchange-traded funds, clearing the way for faster approvals. Summary SEC has greenlighted new generic listing standards for spot crypto ETFs. Rule change eliminates lengthy case-by-case approvals, aligning crypto ETFs with commodity funds. Grayscale’s Digital Large Cap Fund and Bitcoin ETF options also gain approval. The U.S. SEC has approved new generic listing standards that will allow exchanges to fast-track spot crypto ETFs, marking a pivotal shift in U.S. digital asset regulation. According to a Sept. 17 press release, the SEC voted to approve rule changes from Nasdaq, NYSE Arca, and Cboe BZX, enabling them to list and trade commodity-based trust shares, including those holding spot digital assets, without submitting individual proposals for each product. A streamlined path for crypto ETFs Under the new rules, an ETF can be listed without SEC sign-off if its underlying asset trades on a market with surveillance-sharing agreements, has active CFTC-regulated futures contracts for at least six months, or already represents at least 40% of an existing listed ETF. This brings crypto ETFs in line with traditional commodity-based funds under Rule 6c-11, eliminating a process that could take up to 240 days. SEC chair Paul Atkins said the move was designed to “maximize investor choice and foster innovation” while ensuring the U.S. remains the leading market for digital assets. Jamie Selway, director of the division of trading and markets, called the framework “a rational, rules-based approach” that balances access with investor protection. First products already approved Alongside the new standards, the SEC cleared the listing of the Grayscale Digital Large Cap Fund, which tracks spot assets based on the CoinDesk 5 Index. It also approved trading of options tied to the Cboe Bitcoin U.S. ETF Index and its mini version, with…
Share
BitcoinEthereumNews2025/09/18 14:04
Scott Melker Sees Bitcoin Upside Despite Growing Caution in Price Forecasts

Scott Melker Sees Bitcoin Upside Despite Growing Caution in Price Forecasts

Analysts avoid firm Bitcoin price targets after past misses, but Melker still expects new highs despite current market weakness. Bitcoin price forecasts have grown
Share
LiveBitcoinNews2026/01/21 02:15